CYP7A1 Polyclonal antibody
CYP7A1 Polyclonal Antibody for WB, IHC, ELISA
Host / Isotype
Rabbit / IgG
Reactivity
human and More (3)
Applications
WB, IHC, ELISA
Conjugate
Unconjugated
Cat no : 18054-1-AP
Synonyms
Validation Data Gallery
Tested Applications
| Positive WB detected in | HepG2 cells, HuH-7 cells, L02 cells, SMMC-7721 cells |
| Positive IHC detected in | human liver tissue, human liver cancer tissue Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0 |
Recommended dilution
| Application | Dilution |
|---|---|
| Western Blot (WB) | WB : 1:1000-1:6000 |
| Immunohistochemistry (IHC) | IHC : 1:50-1:500 |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
Published Applications
| WB | See 12 publications below |
| IHC | See 2 publications below |
Product Information
18054-1-AP targets CYP7A1 in WB, IHC, ELISA applications and shows reactivity with human samples.
| Tested Reactivity | human |
| Cited Reactivity | human, mouse, rat, hamster |
| Host / Isotype | Rabbit / IgG |
| Class | Polyclonal |
| Type | Antibody |
| Immunogen | CYP7A1 fusion protein Ag12572 |
| Full Name | cytochrome P450, family 7, subfamily A, polypeptide 1 |
| Calculated Molecular Weight | 504 aa, 58 kDa |
| Observed Molecular Weight | 58 kDa |
| GenBank Accession Number | BC101777 |
| Gene Symbol | CYP7A1 |
| Gene ID (NCBI) | 1581 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Antigen affinity purification |
| Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol pH 7.3. |
| Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA. |
Background Information
CYP7A1 (Cytochrome P450 Family 7 Subfamily A Member 1), is a cholesterol 7alpha-hydroxylase, catalyzing the first and rate-limiting step in the neutral or classic pathway for bile acid biosynthesis. CYP7A1 is a postulated gene modifier of colorectal cancer risk and target for the therapeutic bile acid, ursodeoxycholic acid (UDCA). The CYP7A1 enzyme controls the rate-limiting step of the catabolism of cholesterol into bile acids in the liver.
Protocols
| Product Specific Protocols | |
|---|---|
| WB protocol for CYP7A1 antibody 18054-1-AP | Download protocol |
| IHC protocol for CYP7A1 antibody 18054-1-AP | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
Publications
| Species | Application | Title |
|---|---|---|
Cell Mol Gastroenterol Hepatol Endoplasmic Reticulum Stress Regulates Hepatic Bile Acid Metabolism in Mice. | ||
Cell Mol Gastroenterol Hepatol A Mitochondrial DNA Variant Elevates the Risk of Gallstone Disease by Altering Mitochondrial Function. | ||
Ecotoxicol Environ Saf Triclosan exposure causes abnormal bile acid metabolism through IL-1β-NF-κB-Fxr signaling pathway | ||
J Ethnopharmacol Multi-omics and chemical profiling approaches to understand the material foundation and pharmacological mechanism of Sophorae Tonkinensis Radix et Rhizome-induced liver injury in mice | ||
J Lipid Res Hepatic Deletion of X-box Binding Protein 1 Impairs Bile Acid Metabolism in Mice. | ||
Toxicol Sci Hepatic, metabolic and toxicity evaluation of repeated oral administration of SnS2 nanoflowers in mice. |
